2. Cell Cycle/DNA Damage
  3. CDK
  4. Anticancer agent 299

Anticancer agent 299 (compound P12) is a cell-cycle inhibitor, senescence inducer, apoptosis inducer, and antiproliferative agent. Anticancer agent 299 exhibits selective activity against cancer cells with minimal effects on non-tumoral chondrocyte cells at relevant concentrations. Anticancer agent 299 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma.

For research use only. We do not sell to patients.

Anticancer agent 299

Anticancer agent 299 Chemical Structure

CAS No. : 1414873-26-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anticancer agent 299 Related Antibodies

Top Publications Citing Use of Products

View All CDK Isoform Specific Products:

View All Isoforms
CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anticancer agent 299 (compound P12) is a cell-cycle inhibitor, senescence inducer, apoptosis inducer, and antiproliferative agent. Anticancer agent 299 exhibits selective activity against cancer cells with minimal effects on non-tumoral chondrocyte cells at relevant concentrations. Anticancer agent 299 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma[1].

In Vitro

Anticancer agent 299 (P12) (5-50 μM; 7 days) reduces colony-forming capacity in MCF7 and A375 cells with IC50 values of 30.22 μM and 2.915 μM, respectively, and has minimal effect on non-tumoral TC28a2 cells at 5-35 μM[1].
Anticancer agent 299 (P12) (5 μM; 12 days MCF7 treatment, 4 days A375 measurement) reduces spheroid area in MCF7 cells after 8 and 12 days and in A375 cells after 4 days[1].
Anticancer agent 299 (P12) (5 μM; 7days) reduces the proportion of G2/M phase cells in MCF7 (to 15.65%) and A375 (to 1.94%) cells[1].
Anticancer agent 299 (P12) (5 μM; 7 days) upregulates G1/S and S-phase entry genes in MCF7 cells and downregulates those genes in A375 cells[1].
Anticancer agent 299 (P12) (5 μM; 7 days) increases the expression of senescence-associated genes (p21, p53, IGFBP3, GDF15) in MCF7 and A375 cells[1].
Anticancer agent 299 (P12) (5 μM; 7 days) upregulates SASP factors (IL-6, IL-8) in MCF7 cells but not in A375 cells[1].
Anticancer agent 299 (P12) (≥4 days) increases early apoptosis in MCF7 and A375 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anticancer agent 299 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: MCF7, A375, TC28a2
Concentration: 5, 20, 35, 50 μM (MCF7, A375 colony formation); 5, 20, 35, 50 μM (TC28a2 viability assay)
Incubation Time: 7 days
Result: Significantly reduced the colony-forming capacity of MCF7 and A375 cells in a dose-dependent manner. Achieved an IC50 of 30.22 μM in MCF7 cells and 2.915 μM in A375 cells. Did not produce a significant reduction in the number of adherent viable cells in non-tumoral TC28a2 cells from 5 to 35 μM.

Cell Proliferation Assay[1]

Cell Line: MCF7, A375
Concentration: 5 μM
Incubation Time: 12 days (MCF7 treatment); 4 days (A375 measurement)
Result: Significantly reduced spheroid area of MCF7 cells compared with the untreated control after 8 and 12 days of treatment. Significantly reduced spheroid size of A375 cells after 4 days of culture.

Cell Cycle Analysis[1]

Cell Line: MCF7, A375
Concentration: 5 μM
Incubation Time: 7 days
Result: Reduced the proportion of G2/M phase cells to 15.65% in MCF7 cells (vs. 26.25% untreated) and to 1.94% in A375 cells (vs. 5.44% untreated).

Real Time qPCR[1]

Cell Line: MCF7, A375
Concentration: 5 μM
Incubation Time: 7 days
Result: Significantly upregulated genes associated with G1/S transition and S-phase entry in MCF7 cells. Significantly downregulated key regulators of the G1/S transition and S-phase entry, including CCND1, CDK4, CDK6, and CCNE1, in A375 cells.\nInduced a notable increase in the expression of senescence-associated factors, including p21, p53, IGFBP3, and GDF15, in both MCF7 and A375 cells.\nSignificantly upregulated classical SASP components including IL-6 and IL-8 in MCF7 cells. Did not induce SASP factor expression and showed a trend toward reduced synthesis in A375 cells.
Molecular Weight

435.44

Formula

C25H20F3N3O
CAS No.
SMILES

FC(F)(C1=CC=C(C=C1)C2=CC(C3=CC=CC4=C3C=CC=C4)=NC(N5CCOCC5)=N2)F
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anticancer agent 299 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anticancer agent 2991414873-26-9Anticancer agent299Anticancer agent-299CDKCyclin dependent kinaseCDK4A375 cellsCyclin E1BRAF-mutant melanomaMCF7 cellsCyclin D1ER+/HER2? breast cancerp21TC28a2 cellsCDK6Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anticancer agent 299
Cat. No.:
HY-181130
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.